Sebetralstat is an investigational new drug that is being evaluated for the treatment of hereditary angioedema.[1] It is a plasma kallikrein inhibitor.[2]
References
- ^ "Sebetralstat - KalVista Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
- ^ Davie RL, Edwards HJ, Evans DM, Hodgson ST, Stocks MJ, Smith AJ, et al. (October 2022). "Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema". Journal of Medicinal Chemistry. 65 (20): 13629–13644. doi:10.1021/acs.jmedchem.2c00921. PMC 9620001. PMID 36251573.